Pharmacokinetic Model of Oral Levodopa and Role of Carbidopa in Parkinsonian Patients

Yoshikatsu Mizutani, Takaaki Hasegawa, Toshitaka Nabeshima, Yoshikatsu Mizutani, Michiko Ogawa, Yoshiki Okada

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

A pharmacokinetic model of oral levodopa is proposed to elucidate the effects of carbidopa on the pharmacokinetics of levodopa. The propriety of the model was evaluated by simultaneous computer Multi-Line fitting for the plasma concentration-time data of levodopa and dopamine-3-O-sulfate (DA-S), a major metabolite of levodopa, after oral administration of three different levodopa doses to parkinsonian patients. Plasma profiles of levodopa and DA-S were also determined in 12 parkinsonian patients during daily oral administration of Neodopaston ® , a levodopa preparation containing carbidopa in tablet form. We investigated the role of carbidopa by comparing the populational mean parameters calculated in the levodopa alone model with those obtained in patients coadministered levodopa and carbidopa. The results indicated that the pharmacokinetics of levodopa coadministered with carbidopa were dose-independent and that carbidopa reduces the first-pass metabolism of levodopa in the gut wall to less than 10% of the dose absorbed, and decreases the systemic clearance of levodopa by 35-39%. The proposed pharmacokinetic model and the evaluation of carbidopa in this study will provide useful information for the development of drug delivery systems for levodopa or catechol-O-methyltransferase inhibitors, for further stabilization of plasma concentrations of levodopa in parkinsonian patients.

Original languageEnglish
Pages (from-to)1729-1737
Number of pages9
JournalBiological and Pharmaceutical Bulletin
Volume18
Issue number12
DOIs
Publication statusPublished - 01-01-1995
Externally publishedYes

Fingerprint

Levodopa
Pharmacokinetics
Carbidopa
levodopa drug combination carbidopa
Oral Administration
Drug Delivery Systems
Tablets

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science

Cite this

Mizutani, Yoshikatsu ; Hasegawa, Takaaki ; Nabeshima, Toshitaka ; Mizutani, Yoshikatsu ; Ogawa, Michiko ; Okada, Yoshiki. / Pharmacokinetic Model of Oral Levodopa and Role of Carbidopa in Parkinsonian Patients. In: Biological and Pharmaceutical Bulletin. 1995 ; Vol. 18, No. 12. pp. 1729-1737.
@article{ceaac09fe14d4b7083a3ce5c024d8d7c,
title = "Pharmacokinetic Model of Oral Levodopa and Role of Carbidopa in Parkinsonian Patients",
abstract = "A pharmacokinetic model of oral levodopa is proposed to elucidate the effects of carbidopa on the pharmacokinetics of levodopa. The propriety of the model was evaluated by simultaneous computer Multi-Line fitting for the plasma concentration-time data of levodopa and dopamine-3-O-sulfate (DA-S), a major metabolite of levodopa, after oral administration of three different levodopa doses to parkinsonian patients. Plasma profiles of levodopa and DA-S were also determined in 12 parkinsonian patients during daily oral administration of Neodopaston {\circledR} , a levodopa preparation containing carbidopa in tablet form. We investigated the role of carbidopa by comparing the populational mean parameters calculated in the levodopa alone model with those obtained in patients coadministered levodopa and carbidopa. The results indicated that the pharmacokinetics of levodopa coadministered with carbidopa were dose-independent and that carbidopa reduces the first-pass metabolism of levodopa in the gut wall to less than 10{\%} of the dose absorbed, and decreases the systemic clearance of levodopa by 35-39{\%}. The proposed pharmacokinetic model and the evaluation of carbidopa in this study will provide useful information for the development of drug delivery systems for levodopa or catechol-O-methyltransferase inhibitors, for further stabilization of plasma concentrations of levodopa in parkinsonian patients.",
author = "Yoshikatsu Mizutani and Takaaki Hasegawa and Toshitaka Nabeshima and Yoshikatsu Mizutani and Michiko Ogawa and Yoshiki Okada",
year = "1995",
month = "1",
day = "1",
doi = "10.1248/bpb.18.1729",
language = "English",
volume = "18",
pages = "1729--1737",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "12",

}

Pharmacokinetic Model of Oral Levodopa and Role of Carbidopa in Parkinsonian Patients. / Mizutani, Yoshikatsu; Hasegawa, Takaaki; Nabeshima, Toshitaka; Mizutani, Yoshikatsu; Ogawa, Michiko; Okada, Yoshiki.

In: Biological and Pharmaceutical Bulletin, Vol. 18, No. 12, 01.01.1995, p. 1729-1737.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pharmacokinetic Model of Oral Levodopa and Role of Carbidopa in Parkinsonian Patients

AU - Mizutani, Yoshikatsu

AU - Hasegawa, Takaaki

AU - Nabeshima, Toshitaka

AU - Mizutani, Yoshikatsu

AU - Ogawa, Michiko

AU - Okada, Yoshiki

PY - 1995/1/1

Y1 - 1995/1/1

N2 - A pharmacokinetic model of oral levodopa is proposed to elucidate the effects of carbidopa on the pharmacokinetics of levodopa. The propriety of the model was evaluated by simultaneous computer Multi-Line fitting for the plasma concentration-time data of levodopa and dopamine-3-O-sulfate (DA-S), a major metabolite of levodopa, after oral administration of three different levodopa doses to parkinsonian patients. Plasma profiles of levodopa and DA-S were also determined in 12 parkinsonian patients during daily oral administration of Neodopaston ® , a levodopa preparation containing carbidopa in tablet form. We investigated the role of carbidopa by comparing the populational mean parameters calculated in the levodopa alone model with those obtained in patients coadministered levodopa and carbidopa. The results indicated that the pharmacokinetics of levodopa coadministered with carbidopa were dose-independent and that carbidopa reduces the first-pass metabolism of levodopa in the gut wall to less than 10% of the dose absorbed, and decreases the systemic clearance of levodopa by 35-39%. The proposed pharmacokinetic model and the evaluation of carbidopa in this study will provide useful information for the development of drug delivery systems for levodopa or catechol-O-methyltransferase inhibitors, for further stabilization of plasma concentrations of levodopa in parkinsonian patients.

AB - A pharmacokinetic model of oral levodopa is proposed to elucidate the effects of carbidopa on the pharmacokinetics of levodopa. The propriety of the model was evaluated by simultaneous computer Multi-Line fitting for the plasma concentration-time data of levodopa and dopamine-3-O-sulfate (DA-S), a major metabolite of levodopa, after oral administration of three different levodopa doses to parkinsonian patients. Plasma profiles of levodopa and DA-S were also determined in 12 parkinsonian patients during daily oral administration of Neodopaston ® , a levodopa preparation containing carbidopa in tablet form. We investigated the role of carbidopa by comparing the populational mean parameters calculated in the levodopa alone model with those obtained in patients coadministered levodopa and carbidopa. The results indicated that the pharmacokinetics of levodopa coadministered with carbidopa were dose-independent and that carbidopa reduces the first-pass metabolism of levodopa in the gut wall to less than 10% of the dose absorbed, and decreases the systemic clearance of levodopa by 35-39%. The proposed pharmacokinetic model and the evaluation of carbidopa in this study will provide useful information for the development of drug delivery systems for levodopa or catechol-O-methyltransferase inhibitors, for further stabilization of plasma concentrations of levodopa in parkinsonian patients.

UR - http://www.scopus.com/inward/record.url?scp=0029609153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029609153&partnerID=8YFLogxK

U2 - 10.1248/bpb.18.1729

DO - 10.1248/bpb.18.1729

M3 - Article

VL - 18

SP - 1729

EP - 1737

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 12

ER -